Story perspectives

AbbVie’s Emblaveo: FDA Approves Breakthrough Antibiotic for Resistant Infections

2/8/2025

44 8

Summary

Story summary

AbbVie has secured FDA approval for Emblaveo, a groundbreaking fixed-dose intravenous antibiotic that combines aztreonam and avibactam. Designed for adults battling complicated intra-abdominal infections with few treatment options, Emblaveo targets resistant Gram-negative bacteria. Set to launch in the U.S. in Q3 2025, this innovation is a crucial step in the fight against the looming crisis of antimicrobial resistance, which could claim millions of lives by 2050.

1 of 1

Story summary

AbbVie has secured FDA approval for Emblaveo, a groundbreaking fixed-dose intravenous antibiotic that combines aztreonam and avibactam. Designed for adults battling complicated intra-abdominal infections with few treatment options, Emblaveo targets resistant Gram-negative bacteria. Set to launch in the U.S. in Q3 2025, this innovation is a crucial step in the fight against the looming crisis of antimicrobial resistance, which could claim millions of lives by 2050.